Compumedics Appoints U.S. MedTech Leader Christopher Barys as Non-Executive Director to Accelerate U.S. Growth and Capital Market Strategy

Key Highlights

• Board Renewal: Appointment of Christopher R. Barys, former executive at Johnson & Johnson, Medtronic, Philips Healthcare, and Edwards Lifesciences.
• U.S. Growth Activation: Direct access to U.S. MedTech networks, partners, and capital markets to accelerate Somfit® and OrionMEG® commercialisation.
• Capital Market Re-Alignment: CMP currently trades at ~1× revenues compared with global MedTech SaaS peers at 4–8×, highlighting significant re-rating potential.
• Performance Momentum: FY25 Sales orders +22% YoY ($63.4m), Somfit® SaaS +49% revenue growth, OrionMEG® ~$15m secured FY26 pipeline; Total~$20m, China alone (US OrionMEG® launch targeted for FY26).
• Strategic Execution: Structured partner engagement, investor relations program, and capital event pathways under strengthened Board leadership.

Compumedics Limited (ASX: CMP), a global leader in sleep diagnostics, brain imaging, and neurotechnology, today announces the appointment of Christopher R. Barys as Non-Executive Director, effective immediately.

Mr. Barys is a highly accomplished U.S. MedTech executive with over 30 years of leadership at world-class companies including Johnson & Johnson, Medtronic, Edwards Lifesciences, Philips Healthcare, and most recently as CEO of On Target Laboratories. His experience spans scaling $1B+ businesses, securing FDA approvals, driving strategic M&A, and building global commercial franchises.

This appointment strengthens CMP’s Board to support its capital markets strategy, U.S. growth execution, and investor engagement program, directly addressing the Company’s valuation gap relative to global peers.

Message Qualification & Strategic Detail

• Board Renewal for Capital Market Alignment: Mr. Barys’ track record in strategic deal-making, capital events, and U.S. investor networks positions CMP to execute its planned uplift initiatives.
• Somfit® SaaS Growth: U.S. launch and IDTF partnerships underway, tapping into a $150–300m domestic opportunity. Global pharma partnerships provide further upside.
• OrionMEG® Brain Imaging: Five systems sold into China with FY26 revenue recognition (~$15m). U.S. market entry progressing with validation from UCSD.
• FY25 Performance: Sales orders grew +22% YoY to $63.4m, gross margins at 55%, and Somfit® SaaS increased +49% YoY.
• FY26 Outlook, the company expects FY26 revenue to exceed $70m with EBITDA of approximately $9m, driven by accelerating Somfit® adoption, OrionMEG® deliveries, and ongoing SaaS expansion.
• Capital Strategy: The strengthened Board will pursue structured strategic partner deals, U.S.-led investor relations, and potential spinout pathways for Somfit® and OrionMEG®.

Compumedics Chairman, Dr David Burton, commented:

“The addition of Chris Barys to the Board is a defining step in aligning Compumedics with the U.S. capital markets and accelerating our global growth platforms. Chris brings a proven ability to scale MedTech businesses, execute strategic partnerships, and engage the U.S. investor ecosystem — all critical to unlocking the true value of Compumedics.”

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronishe GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton                                                   
Executive Chairman, CEO                                             
P: +61 3 8420 7300                                
F: +61 3 8420 7399                               

David Lawson
Director, CFO
 P: + 61 3 8420 7300
 F: +61 3 8420 7399

Authorised for lodgment by Compumedics Limited’s Board of Directors